Project Grant R61AR085647
Award Date 8/10/25
Completion Date 7/31/28
Dollars Obligated $331K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $465,663 Project Grant was awarded on May 6, 2025 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant supports research to optimize the bone surface targeting of therapeutic antibodies for the treatment of osteoporosis, a common bone disease affecting 10 million U.S. adults. The project aims to increase the local concentration and efficacy of osteoporosis...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $413,655 on August 1, 2025 to Arizona State University (ASU) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop biomaterials with temporal control of proteins, such as Bone Morphogenetic Proteins (BMPs), to enhance bone repair. The research aims to mimic natural extracellular matrix interactions and synergies...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $676,841 Project Grant titled "LEVERAGING HUMAN MUSCULOSKELETAL DEVELOPMENT TO IDENTIFY CAUSAL DISEASE VARIANTS" to President and Fellows of Harvard College. The award period runs from August 1, 2025 to July 31, 2030 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The objective of the project is to conduct targeted functional genomic studies...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to comparatively assess the therapeutic potential of combined anabolic therapy versus the current standard-of-care single-drug approach in postmenopausal women at high risk of fragility fracture. The $1,175,680 award, with a performance period from September 2024 to August 2027, will be used by...
- This $667,125 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), aims to develop a long-lasting, bone-targeted gene therapy for Osteogenesis Imperfecta (OI), the most common bone fragility disease. The University of Massachusetts Medical School (UMMS) will use a novel recombinant adeno-associated virus (rAAV) vector with bone-specific...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), provides $588,302 to The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the role of glutamine metabolism in regulating osteoclast differentiation and bone resorption. The research aims to: 1) establish the necessity and sufficiency of glutaminase (GLS)...
- This $159,594 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to identify new therapeutic targets for osteogenesis imperfecta (OI), a rare genetic bone disorder. The award recipient, the Research Foundation of the City University of New York (RFCUNY), will investigate the intracellular signaling and extracellular matrix mechanisms...
- The federal Project Grant award of $445,217 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the regulatory mechanisms of osteoclasts. Osteoclasts are cells primarily responsible for bone resorption, and their dysregulation is key to the pathophysiology of bone diseases such as osteoporosis, rheumatoid arthritis, and lytic bone metastasis. The...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $386,481 to the University of Connecticut Health Center to research cellular therapy approaches for treating osteogenesis imperfecta (OI), a genetic bone disorder. The project aims to evaluate different stem/progenitor cell populations, determine the mechanisms by which irradiation improves...